Open AccessHuman Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid‐Dependent Mechanism
Author(s) -
Rozenberg Ayal,
Rezk Ayman,
Boivin Marie-Noëlle,
Darlington Peter J.,
Nyirenda Mukanthu,
Li Rui,
Jalili Farzaneh,
Winer Raz,
Artsy Elinor A.,
Uccelli Antonio,
Reese Jane S.,
Planchon Sarah M.,
Cohen Jeffrey A.,
Bar-Or Amit
Publication year - 2016
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2015-0243
Subject(s) - mesenchymal stem cell , cell sorting , microbiology and biotechnology , peripheral blood mononuclear cell , cd14 , immune system , cytokine , stem cell , prostaglandin e2 , cell , biology , immunology , chemistry , flow cytometry , in vitro , endocrinology , biochemistry
A novel prostaglandin E2‐dependent and myeloid cell‐mediated mechanism by which human mesenchymal stem cells (MSCs) can reciprocally induce human Th17 while suppressing Th1 responses has implications for the use of, as well as monitoring of, MSCs as a potential therapeutic for patients with multiple sclerosis and other immune‐mediated diseases.